| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9db5428d6823098cb526c6c9db4c1ab5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D261-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate |
2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f40e097d78e4a2031ff6b5a8d05c31dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a65f4f5168aa33062ee75f06ff93eef |
| publicationDate |
2021-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112021000913-A2 |
| titleOfInvention |
ISOXAZOL AS RECEPTOR AGONIST FXR |
| abstract |
The present invention relates to compounds of formula (I), their pharmaceutical compositions and their uses, in particular in the treatment and / or Prevention of diseases mediated by FXR |
| priorityDate |
2018-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |